AbCellera Biologics (ABCL) Competitors $2.39 -0.04 (-1.65%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. IMVT, VKTX, XENE, HCM, IBRX, AMRX, MLTX, TWST, VCEL, and MIRMShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Immunovant (IMVT), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), MoonLake Immunotherapeutics (MLTX), Twist Bioscience (TWST), Vericel (VCEL), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Immunovant Viking Therapeutics Xenon Pharmaceuticals HUTCHMED ImmunityBio Amneal Pharmaceuticals MoonLake Immunotherapeutics Twist Bioscience Vericel Mirum Pharmaceuticals Immunovant (NASDAQ:IMVT) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Does the MarketBeat Community prefer IMVT or ABCL? Immunovant received 76 more outperform votes than AbCellera Biologics when rated by MarketBeat users. Likewise, 78.11% of users gave Immunovant an outperform vote while only 75.68% of users gave AbCellera Biologics an outperform vote. CompanyUnderperformOutperformImmunovantOutperform Votes13278.11% Underperform Votes3721.89% AbCellera BiologicsOutperform Votes5675.68% Underperform Votes1824.32% Is IMVT or ABCL more profitable? Immunovant has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -77.94% -69.82% AbCellera Biologics -533.32%-15.73%-12.22% Do analysts recommend IMVT or ABCL? Immunovant currently has a consensus target price of $41.00, indicating a potential upside of 176.28%. AbCellera Biologics has a consensus target price of $7.50, indicating a potential upside of 213.81%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to IMVT or ABCL? In the previous week, Immunovant had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 10 mentions for Immunovant and 6 mentions for AbCellera Biologics. Immunovant's average media sentiment score of 1.16 beat AbCellera Biologics' score of 0.83 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, IMVT or ABCL? Immunovant has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IMVT or ABCL? 47.1% of Immunovant shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 5.9% of Immunovant shares are held by insiders. Comparatively, 28.0% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, IMVT or ABCL? AbCellera Biologics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$259.34M-$2.62-5.66AbCellera Biologics$28.83M24.70-$146.40M-$0.55-4.35 SummaryImmunovant and AbCellera Biologics tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$712.19M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-3.926.6921.6317.68Price / Sales24.70222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book0.605.776.373.94Net Income-$146.40M$142.01M$3.20B$247.45M7 Day Performance10.14%2.88%1.79%0.48%1 Month Performance-5.16%-13.93%-9.41%-7.08%1 Year Performance-40.99%-12.36%9.61%-0.35% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.1306 of 5 stars$2.39-1.6%$7.50+213.8%-41.9%$712.19M$28.83M-3.92500Analyst ForecastNews CoverageGap DownIMVTImmunovant2.3711 of 5 stars$14.14-3.0%$41.00+189.9%-49.2%$2.40BN/A-5.40120Short Interest ↑Positive NewsGap UpVKTXViking Therapeutics4.2639 of 5 stars$21.11-6.7%$95.18+350.9%-65.5%$2.38BN/A-21.2220Upcoming EarningsOptions VolumeNews CoverageXENEXenon Pharmaceuticals1.9313 of 5 stars$30.50+3.7%$57.38+88.1%-20.0%$2.35B$9.43M-10.87210Analyst DowngradeAnalyst RevisionPositive NewsHigh Trading VolumeHCMHUTCHMED2.2859 of 5 stars$13.15-8.6%$19.00+44.5%-18.6%$2.29B$630.20M0.001,988Positive NewsGap DownIBRXImmunityBio1.9476 of 5 stars$2.67-5.8%$12.19+357.0%-46.9%$2.28B$14.75M-2.91590Analyst ForecastNews CoverageAMRXAmneal Pharmaceuticals3.2367 of 5 stars$7.17-2.8%$10.80+50.6%+29.4%$2.23B$2.79B-10.607,600Short Interest ↑Gap DownMLTXMoonLake Immunotherapeutics2.0152 of 5 stars$34.45-7.4%$80.50+133.7%-15.7%$2.23BN/A-27.002Gap DownTWSTTwist Bioscience3.467 of 5 stars$37.01+2.3%$54.10+46.2%+35.1%$2.20B$330.19M-10.90990Positive NewsVCELVericel2.4085 of 5 stars$39.78-5.1%$62.29+56.6%-13.7%$2.01B$237.22M667.63300News CoverageMIRMMirum Pharmaceuticals3.9389 of 5 stars$40.93-2.6%$58.20+42.2%+61.6%$2.00B$336.89M-20.24140Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Immunovant Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors HUTCHMED Competitors ImmunityBio Competitors Amneal Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Twist Bioscience Competitors Vericel Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
